These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7779359)

  • 1. Pharmaceutical aspects of combined vaccines: a manufacturer's perspective.
    Vose JR
    Biologicals; 1994 Dec; 22(4):335-8. PubMed ID: 7779359
    [No Abstract]   [Full Text] [Related]  

  • 2. Manufacturing issues with combining different antigens: a regulatory perspective.
    Falk LA; Arciniega J; McVittie L
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S351-5. PubMed ID: 11709772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manufacturing issues related to combining different antigens: an industry perspective.
    Van Hoof J
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S346-50. PubMed ID: 11709771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory aspects of clinical trials with vaccines.
    Georges AM
    Dev Biol Stand; 1998; 95():69-74. PubMed ID: 9855416
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of current preclinical testing strategies for bacterial vaccines.
    Falk LA; Chandler DK; Richman P
    Dev Biol Stand; 1998; 95():25-9. PubMed ID: 9855411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Japanese perspective regarding regulatory concerns for biotechnology drugs and their scientific basis.
    Hayakawa T
    Bioprocess Technol; 1991; 13():468-98. PubMed ID: 1367147
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives on the manufacture of combination vaccines.
    Vose JR
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S334-9. PubMed ID: 11709769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety evaluation of combination vaccines.
    Midthun K; Horne AD; Goldenthal KL
    Dev Biol Stand; 1998; 95():245-9. PubMed ID: 9855438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and future trends in vaccine regulation--USA.
    Falk LA; Ball LK
    Vaccine; 2001 Feb; 19(13-14):1567-72. PubMed ID: 11166876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of human-use adjuvants.
    Kenney RT; Edelman R
    Expert Rev Vaccines; 2003 Apr; 2(2):167-88. PubMed ID: 12899569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharma goes to work. Introduction.
    Mervis J
    Science; 2005 Jul; 309(5735):721. PubMed ID: 16051780
    [No Abstract]   [Full Text] [Related]  

  • 13. Potency tests of combination vaccines.
    Taffs RE
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S362-6. PubMed ID: 11709774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The system of mutual recognition of batch release in the EU--implications for combined vaccines.
    Dobbelaer R
    Biologicals; 1994 Dec; 22(4):377-80. PubMed ID: 7779364
    [No Abstract]   [Full Text] [Related]  

  • 15. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases.
    Fuller DH; Loudon P; Schmaljohn C
    Methods; 2006 Sep; 40(1):86-97. PubMed ID: 16997717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prototypical process for creating evidentiary standards for biomarkers and diagnostics.
    Altar CA; Amakye D; Bounos D; Bloom J; Clack G; Dean R; Devanarayan V; Fu D; Furlong S; Hinman L; Girman C; Lathia C; Lesko L; Madani S; Mayne J; Meyer J; Raunig D; Sager P; Williams SA; Wong P; Zerba K
    Clin Pharmacol Ther; 2008 Feb; 83(2):368-71. PubMed ID: 18091762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The brains behind blockbusters.
    Couzin J
    Science; 2005 Jul; 309(5735):728. PubMed ID: 16051786
    [No Abstract]   [Full Text] [Related]  

  • 19. Perspectives on the state of combination vaccines: summary of the rapporteur for the International Symposium on Combination Vaccines.
    Hinman AR
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S372-5. PubMed ID: 11709776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.